A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity or Overweight, sponsored by Novo Nordisk A/S. Completed at 37 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.
Among the 36 studies testing cagrilintide in Obesity, this one is the 13th largest by enrollment, is one of 5 that started in 2023, is one of 15 in phase 3, and was the 13th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Greece, Hungary and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–64
Novo Nordisk A/S · Sites in Germany
Ages 18–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
36 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 154 across the 36 interventional studies. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 36 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 55th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 62 in phase 3, and was the 109th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
8 of the studies testing cagrilintide in Obesity that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07557953Novo Nordisk A/SA Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | 2027-04-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 36 studies testing cagrilintide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age above or equal to 18 years at the time of signing
For participants with Type 2 diabetes (T2D) at screening the following criteria also apply:
Exclusion Criteria:
For participants without T2D at screening:
For participants with T2D at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 44 weeks.
Drug: Cagrilintide · Drug: Semaglutide
Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 44 weeks.
Drug: Semaglutide · Drug: Placebo Semaglutide
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 44 weeks.
Drug: Placebo Semaglutide · Drug: Placebo Cagrilintide
Participants will receive 2.4 mg cagrilintide subcutaneously.
Participants will receive 2.4 mg semaglutide subcutaneously.
Participants will receive placebo matched to semaglutide subcutaneously.
Participants will receive placebo matched to cagrilintide subcutaneously.
CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 5%
Measured as count of participants
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 20%
Measured as count of participants
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus semaglutide 2.4 mg: Relative change in body weight
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in waist circumference
Measured in centimeter (cm)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 10%
Measured as count of participants
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 15%
Measured as count of participants
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus semaglutide 2.4 mg: Change in waist circumference
Measured in centimeter (cm)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Glycated Haemoglobin (HbA1c)
Measured in percentage points
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Fasting Plasma Glucose (FPG)
Measured as millimole per liter (mmol/L)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in fasting serum insulin
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Systolic Blood Pressure (SBP)
Measured in millimeter of mercury (mmHg)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Diastolic Blood Pressure (DBP)
Measured in millimeter of mercury (mmHg)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in total cholesterol
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in high-density lipoprotein (HDL) cholesterol
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in low-density lipoprotein (LDL) cholesterol
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in very low-density lipoprotein (VLDL) cholesterol
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in triglycerides
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in free fatty acids
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Short Form-36 Version 2.0 (SF- 36v2) Physical Functioning score
Measured as score points. The SF-36v2.0 is a 36-item commonly used generic clinical outcome assessment (COA) instrument measuring health-related quality of life and general health status across disease areas. SF-36v2 questionnaire measures 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint assess the 'physical functioning domain'. The 0-100 scale scores from the SF-36 will be converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 correspond to the mean and standard deviation respectively. A positive change score indicates an improvement since baseline.
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in SF-36v2: Physical Component Summary Score
Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health-related quality of life and general health status across disease areas. SF-36v2 questionnaire measures 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint assess the 'physical component summary'. The 0-100 scale scores from the SF-36 will be converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively. A positive change score indicates an improvement since baseline.
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in SF-36v2: Mental Component Summary score
Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health-related quality of life and general health status across disease areas. SF-36v2 questionnaire measures 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint assess the 'mental component summary'. The 0-100 scale scores from the SF-36 will be converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively. A positive change score indicates an improvement since baseline.
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOLLite- CT) Physical Function score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patient's physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. This endpoint assess the 'physical function score'. The scores range between 0-100 where higher scores indicate a better quality of life. A positive change score indicates an improvement since baseline.
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo: Change in IWQOL-Lite-CT Total score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patient's physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. This endpoint assess the 'total score'. The scores range between 0-100 where higher scores indicate a better quality of life. A positive change score indicates an improvement since baseline.
Time frame: From baseline (week 0) to end of treatment (week 44)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Number of Treatment Emergent Adverse Events (TEAEs)
Measured as count of events
Time frame: From baseline (week 0) to end of study (week 51)
CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Number of Treatment Emergent Serious Adverse Events (TESAEs)
Measured as count of events
Time frame: From baseline (week 0) to end of study (week 51)
Number of clinically significant hypoglycaemic episodes (level 2) (lesser than 3.0 mmol/L (54 milligrams per deciliter[mg/dL]), confirmed by BG meter) (only for participants with Type 2 diabetes (T2D) at screening)
Measured as count of episodes
Time frame: From baseline (week 0) to end of study (week 51)
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold (only for participants with T2D at screening)
Measured as count of episodes
Time frame: From baseline (week 0) to end of study (week 51)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in Jan 2025, 16 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 16 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide